BlueGnome develops tests to investigate genetic disorders, focusing on intellectual disabilities, cancer and infertility. Its customers are spread worldwide and include the NHS, IVF clinics and private hospitals. The company was spun out of Cambridge University in 2002 by Nick Haan and Graham Snudden, who still lead the business. They are now looking to open offices in America, where the company generates roughly a third of its turnover, as well as in Singapore. Sales have grown 70% a year from £1.4m in 2007 to £6.8m in 2010.
This profile reflects the company at time of publication and does not reflect any changes that may have subsequently occurred. Fast Track and its sponsors do not endorse, guarantee or recommend investment in any of the companies.